Steven J Jubelirer, MD

Dr. Steven J. Jubelirer

Claim this profile

West Virginia University Charleston Division

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
30 reported clinical trials
78 drugs studied

Area of expertise

1

Lung Cancer

Steven J. Jubelirer has run 9 trials for Lung Cancer. Some of their research focus areas include:

Stage III
Stage IV
Stage II
2

Non-Small Cell Lung Cancer

Steven J. Jubelirer has run 7 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage III
Stage II
Stage IV

Affiliated Hospitals

Image of trial facility.

West Virginia University Charleston Division

Clinical Trials Steven J. Jubelirer is currently running

Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.

Recruiting

2 awards

Phase 3

31 criteria

Image of trial facility.

Radiation Therapy + Cisplatin

for Head and Neck Cancer

This trial is studying if using a specific type of energy treatment alone or with a drug is better for treating patients with advanced head and neck cancer after surgery. The energy treatment kills cancer cells, and the drug helps by stopping their growth or killing them. The drug has been used for many years in the treatment of advanced cancers, including head and neck cancers, and is known for its ability to enhance the effects of the energy treatment.

Recruiting

1 award

Phase 2

19 criteria

More about Steven J. Jubelirer

Clinical Trial Related

6 years of experience running clinical trials · Led 30 trials as a Principal Investigator · 6 Active Clinical Trials

Treatments Steven J. Jubelirer has experience with

  • Atezolizumab
  • Paclitaxel
  • Nivolumab
  • Carboplatin
  • Bevacizumab
  • Ipilimumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Steven J. Jubelirer specialize in?

Is Steven J. Jubelirer currently recruiting for clinical trials?

Are there any treatments that Steven J. Jubelirer has studied deeply?

What is the best way to schedule an appointment with Steven J. Jubelirer?

What is the office address of Steven J. Jubelirer?

Is there any support for travel costs?